home / stock / life / life news


LIFE News and Press, aTyr Pharma Inc. From 01/18/24

Stock Information

Company Name: aTyr Pharma Inc.
Stock Symbol: LIFE
Market: NASDAQ
Website: atyrpharma.com

Menu

LIFE LIFE Quote LIFE Short LIFE News LIFE Articles LIFE Message Board
Get LIFE Alerts

News, Short Squeeze, Breakout and More Instantly...

LIFE - aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appoi...

LIFE - aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation for its lead therapeutic ...

LIFE - aTyr Pharma files for $300M mixed-shelf offering

2023-11-13 07:24:24 ET More on aTyr Pharma Seeking Alpha’s Quant Rating on aTyr Pharma Historical earnings data for aTyr Pharma Financial information for aTyr Pharma For further details see: aTyr Pharma files for $300M mixed-shelf offering

LIFE - aTyr Pharma GAAP EPS of -$0.20, revenue of $0.3M

2023-11-10 11:04:53 ET More on aTyr Pharma Seeking Alpha’s Quant Rating on aTyr Pharma Historical earnings data for aTyr Pharma Financial information for aTyr Pharma For further details see: aTyr Pharma GAAP EPS of -$0.20, revenue of $0.3M

LIFE - aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated patient dosing. Ended the third quarter of 2023 with $105.6 million in...

LIFE - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

LIFE - Expected earnings - aTyr Pharma Inc.

aTyr Pharma Inc. (LIFE) is expected to report $-0.21 for Q3 2023

LIFE - aTyr Pharma to Present at November Investor Conferences

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President an...

LIFE - aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT(TM) Study of Efzofitimod in Patients with SSc-ILD

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the fir...

LIFE - Catalyst watch: Tesla earnings, Jerome Powell speech, UAW drama and Baidu event

2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

Previous 10 Next 10